Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fasinumab for vertebral fracture pain
NCT01001715Phase 2Terminated
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Nov 2009
- Primary completion
- Jan 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in back pain comparing REGN475/SAR164877 with Placebo (2 arms). Primary endpoint: Mean change from baseline in pain intensity as assessed by Pain Intensity Numeric Rating Scale (PI-NRS) at 4 weeks. Started Nov 2009; status: terminated.
02
Drugs
fasinumab
03
Conditions
back pain
Beyond the preview
Go deeper on NCT01001715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01001715.